Entellus Medical (ENTL) Upgraded at TheStreet

Entellus Medical (NASDAQ:ENTL) was upgraded by equities researchers at TheStreet from a “d” rating to a “c-” rating in a research note issued to investors on Thursday.

Several other research analysts also recently issued reports on the company. William Blair downgraded Entellus Medical from an “outperform” rating to a “market perform” rating in a research report on Friday, December 8th. ValuEngine upgraded Entellus Medical from a “sell” rating to a “hold” rating in a report on Thursday, December 7th. Zacks Investment Research downgraded Entellus Medical from a “buy” rating to a “hold” rating in a report on Tuesday, October 31st. Canaccord Genuity reiterated a “hold” rating and issued a $17.00 price target on shares of Entellus Medical in a report on Tuesday, October 17th. Finally, Piper Jaffray Companies reiterated a “buy” rating and issued a $21.00 price target on shares of Entellus Medical in a report on Tuesday, August 22nd. One research analyst has rated the stock with a sell rating, five have issued a hold rating and two have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $20.40.

Entellus Medical (NASDAQ:ENTL) opened at $24.63 on Thursday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.71 and a current ratio of 1.92. Entellus Medical has a 12-month low of $11.47 and a 12-month high of $24.88.

In other Entellus Medical news, Director Brian E. Farley sold 3,972 shares of the business’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $19.10, for a total value of $75,865.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Timothy B. Petrick sold 2,000 shares of the business’s stock in a transaction on Friday, September 22nd. The shares were sold at an average price of $18.00, for a total transaction of $36,000.00. The disclosure for this sale can be found here. Insiders sold a total of 168,469 shares of company stock valued at $3,718,611 over the last quarter. 7.70% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in ENTL. Vanguard Group Inc. grew its stake in shares of Entellus Medical by 77.8% during the 1st quarter. Vanguard Group Inc. now owns 424,823 shares of the medical technology company’s stock valued at $5,862,000 after buying an additional 185,833 shares during the period. Geode Capital Management LLC grew its stake in shares of Entellus Medical by 87.0% during the 1st quarter. Geode Capital Management LLC now owns 97,417 shares of the medical technology company’s stock valued at $1,344,000 after buying an additional 45,310 shares during the period. Schwab Charles Investment Management Inc. grew its stake in shares of Entellus Medical by 53.3% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 28,330 shares of the medical technology company’s stock valued at $391,000 after buying an additional 9,855 shares during the period. Bank of America Corp DE grew its stake in shares of Entellus Medical by 53.8% during the 1st quarter. Bank of America Corp DE now owns 7,418 shares of the medical technology company’s stock valued at $102,000 after buying an additional 2,594 shares during the period. Finally, Goldman Sachs Group Inc. purchased a new stake in shares of Entellus Medical during the 1st quarter valued at $423,000. 78.76% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Entellus Medical (ENTL) Upgraded at TheStreet” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://www.com-unik.info/2017/12/16/entellus-medical-entl-upgraded-at-thestreet.html.

Entellus Medical Company Profile

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Analyst Recommendations for Entellus Medical (NASDAQ:ENTL)

What are top analysts saying about Entellus Medical? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Entellus Medical and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit